Text Size

Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension

This study has been completed.
Sponsor:
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
NCT00741078
First received: August 20, 2008
Last updated: August 28, 2008
Last verified: August 2008
History of Changes
  Purpose

The investigators hypothesized combination therapy would be superior to monotherapy.


Condition Intervention Phase
Hypertension
 Drug: statin, amlodipine
 Phase 4

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Official Title: Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Gachon University Gil Medical Center:

Study Start Date: December 2004
Study Completion Date: August 2008
Arms Assigned Interventions
Experimental: atorvastatin, amlodipine Drug: statin, amlodipine

  Eligibility

Ages Eligible for Study:   25 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hypertension

Exclusion Criteria:

  • Chronic renal disease
  • Severe hypertension
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00741078

Locations
Korea, Republic of
Gil Medical Center
Incheon, Korea, Republic of, 405-760
Sponsors and Collaborators
Gachon University Gil Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00741078     History of Changes
Other Study ID Numbers: GMC-200504
Study First Received: August 20, 2008
Last Updated: August 28, 2008
Health Authority: South Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:
endothelial
function
insulin
sensitivity

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Amlodipine
Atorvastatin
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
 Therapeutic Uses
Vasodilator Agents
Antihypertensive Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Enzyme Inhibitors
Lipid Regulating Agents

ClinicalTrials.gov processed this record on May 22, 2013